The Unrecognized Prevalence of Primary Aldosteronism
Authors: R. Haridian Sosa Barrios, Miriam Menacho-Román, A.L. Mataix, Fernando Liaño García
Journal: Annals of Internal Medicine (2020)

Letters20 October 2020The Unrecognized Prevalence of Primary AldosteronismR. Haridian Sosa Barrios, MD, MSc, Miriam Menacho-Román, MD, MSc, A.L. Mataix, MD, and Fernando Liaño García, MD, PhDR. Haridian Sosa Barrios, MD, MScHospital Universitario Ramón y Cajal, Madrid, Spain (R.H.S., M.M.)Search for more papers by this author, Miriam Menacho-Román, MD, MScHospital Universitario Ramón y Cajal, Madrid, Spain (R.H.S., M.M.)Search for more papers by this author, A.L. Mataix, MDServicio Madrileño de Salud SERMAS, Madrid, Spain (A.M.)Search for more papers by this author, and Fernando Liaño García, MD, PhDInstituto de Investigación Biomédica, FIBio-HRC, Madrid, Spain (F.L.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1095 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Brown and colleagues (1) estimated renin-independent aldosterone production using a urinary aldosterone excretion cutoff of 12 µg/24 h in hypertensive and normotensive patients. They found that primary aldosteronism was present in 9.0%, 18.9%, and 24% of normotensive, untreated, and resistantly hypertensive patients, respectively. On the basis of these findings, the authors emphasized that a relevant proportion of patients are mislabeled as having essential hypertension. As such, they open the door to a paradigm change in the concept and treatment of arterial hypertension.A subsequent increase in the prescription of MRAs could be expected. However, the authors do ...References1. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism. A cross-sectional study. Ann Intern Med. 2020;173:10-20. [PMID: 32449886]. doi:10.7326/M20-0065 LinkGoogle Scholar2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. [PMID: 10471456] CrossrefMedlineGoogle Scholar3. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-51. [PMID: 15295047] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Universitario Ramón y Cajal, Madrid, Spain (R.H.S., M.M.)Servicio Madrileño de Salud SERMAS, Madrid, Spain (A.M.)Instituto de Investigación Biomédica, FIBio-HRC, Madrid, Spain (F.L.G.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1095. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Unrecognized Prevalence of Primary Aldosteronism Jenifer M. Brown , Mohammed Siddiqui , David A. Calhoun , Robert M. Carey , Paul N. Hopkins , Gordon H. Williams , and Anand Vaidya The Unrecognized Prevalence of Primary Aldosteronism Georgios P. Piaditis , Grigorios Kaltsas , Athina Markou , and George P. Chrousos The Unrecognized Prevalence of Primary Aldosteronism Anand Vaidya , Jenifer M. Brown , Robert M. Carey , Mohammed Siddiqui , and Gordon H. Williams The Unrecognized Prevalence of Primary Aldosteronism Stefan Pilz , Martin R. Grübler , Verena Theiler-Schwetz , Oliver Malle , and Christian Trummer Metrics 20 October 2020Volume 173, Issue 8Page: 682-683KeywordsAldosteroneExcretionHeart failureHospitalizationsHypertensionLongitudinal studiesMagnetic resonance angiographyMorbidityMortalityPotassium ePublished: 20 October 2020 Issue Published: 20 October 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...